Publication | Closed Access

The BCL2 E17 and SP66 antibodies discriminate 2 immunophenotypically and genetically distinct subgroups of conventionally BCL2-“negative” grade 1/2 follicular lymphomas

Sp66 AntibodiesLymphoid NeoplasiaAutoimmune DiseaseBcl2 E17ImmunologyHematologyPathologyImmunophenotypingImmune SurveillanceImmunotherapyMedicineDistinct Subgroups